# Safety Tolerability, and PK of RYI-018 After Repeat Dosing in Subjects With Non-Alcoholic Fatty Liver Disease (NAFLD)

> **NCT03261739** · PHASE1 · COMPLETED · sponsor: **Bird Rock Bio, Inc.** · enrollment: 84 (actual)

## Conditions studied

- NAFLD

## Interventions

- **BIOLOGICAL:** RYI-018
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT03261739
- **Lead sponsor:** Bird Rock Bio, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-08-28
- **Primary completion:** 2018-08-24
- **Final completion:** 2018-08-24
- **Target enrollment:** 84 (ACTUAL)
- **Last updated:** 2019-03-14

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03261739

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03261739, "Safety Tolerability, and PK of RYI-018 After Repeat Dosing in Subjects With Non-Alcoholic Fatty Liver Disease (NAFLD)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03261739. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*